Premium
Hematopoietic recovery after IEV chemotherapy for malignant lymphoma followed by different cytokines can be monitored by analysis of Gα 16 and CD34
Author(s) -
Pfeilstöcker M.,
Karlic H.,
Salamon J.,
Mühlberger H.,
Pavlova B.,
Strobl H.,
Pittermann E.,
Heinz R.
Publication year - 2000
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/1096-8652(200007)64:3<156::aid-ajh3>3.0.co;2-f
Subject(s) - haematopoiesis , cytokine , cd34 , lymphoma , chemotherapy , cancer research , hematopoietic growth factor , medicine , biology , immunology , oncology , stem cell , genetics
The hematopoiesis‐specific G protein α subunit Gα16 is a specific element in the signal transduction of the early hematopoietic cytokine network. As Gα16 mRNA can be detected in early hematopoietic progenitor cells, RT‐PCR for Gα16 can be used as a sensitive marker of hematopoietic activity. The aim of this study was to test the possible use of Gα16 determinations for monitoring cytokine effects on hematopoietic recovery after chemotherapy in patients. We correlated presence of Gα16 mRNA and CD34 surface antigen with hematopoietic recovery in six lymphoma patients undergoing salvage therapy with different cytokine support (IEV followed by G‐CSF, IL‐3, or placebo). Regardless of different cytokine schedules with different time courses, hematopoietic recovery was always preceded by transcription of Gα16. Monitoring the expression of Gα16 mRNA by RT‐PCR is a highly sensitive diagnostic tool for analyzing hematopoietic recovery after chemotherapy and for characterizing the effects of cytokines on hematopoiesis. Am. J. Hematol. 64:156–160, 2000. © 2000 Wiley‐Liss, Inc.